How Long Before You See Weight Loss on Wegovy?

What happens in the first four weeks — and why the scales may barely move?

It is completely normal to feel faintly frustrated in the opening weeks. You expected a prescription medicine to do something visible, and the number on the scale has barely budged. There is a clinical reason for that. The treatment starts at 0.25 mg weekly, a dose that exists purely to let your body adjust and to reduce the chance of nausea, not to suppress appetite in any meaningful way.

Around week five the prescriber typically moves you to 0.5 mg, and you may start to notice that meals feel more filling and snacking urges fade. For many people, some scale movement appears in weeks four to eight, but this is still early in the dose-escalation process. The 1.0 mg and 1.7 mg stages follow, each lasting roughly four weeks, before you reach the 2.4 mg maintenance dose that was studied in the STEP 1 trial. If you want a clearer sense of how long it typically takes to see weight loss on Wegovy, the picture becomes more meaningful once dose escalation is well underway.

If you want to understand what the full journey looks like, the Wegovy overview page covers the complete dose schedule and what to expect at each stage. One practical note: keeping a weekly log of your weight under consistent conditions (same time of day, same scales) gives you a cleaner picture than daily weigh-ins, which fluctuate with fluid and food.

When do most people start to see noticeable weight loss on Wegovy?

The STEP 1 trial data, published in the NEJM, tracked 1,961 adults without diabetes over 68 weeks. By week 20, participants on semaglutide had already lost around 8–9% of their starting weight on average; by week 68 that had grown to roughly 15%. The curve is steep in the middle months as the maintenance dose beds in, then flatter as the body reaches a new equilibrium.

Clinically, weeks 12 to 28 are often described as the most active phase. Appetite suppression is strong, dose titration is complete or nearly so, and the calorie deficit compounds week on week. If you are curious about how long before weight loss on Wegovy typically begins, the pattern varies by individual but the middle months are where most people see the steepest change. Those who make fewer lifestyle changes still lose weight, but typically less. The licence for Wegovy explicitly requires it to be used alongside a reduced-calorie diet and increased physical activity; this is not optional small print.

For context on what the average figures mean and how individual results vary, the average weight loss on Wegovy page breaks down the trial numbers in more detail. A separate question many people have is how the timeline compares across different medicines; our weight-loss treatment overview covers the options currently available.

What slows results down, and when should you reassess?

Several things can blunt or delay the weight loss. Inconsistent injection timing is one: semaglutide has a long half-life, but skipping or shifting doses disrupts the steady blood-level that keeps appetite in check. The way it is taken also matters, for details on correct injection technique and storage your Patient Information Leaflet and prescriber are the right guides.

Dose tolerance is another variable. Some people cannot reach 2.4 mg because nausea or other gastrointestinal effects at higher steps are difficult to manage. If you plateau before the full maintenance dose, that is important information for your prescriber, not a reason to stop. The NICE appraisal of semaglutide, TA875, notes that if fewer than 5% of starting weight has been lost after six months on the maintenance dose, continuing treatment should be reviewed. That is a formal stopping consideration, not an arbitrary cut-off; it exists because the medicine genuinely does not suit everyone.

Thyroid conditions, certain medications, sleep quality and stress levels all interact with weight in ways that have nothing to do with Wegovy specifically. Honest expectation-setting matters here. The medicine is effective for a large proportion of the people who take it, but it is not uniform, and a prescriber who knows your full picture can help you interpret a plateau. Our FAQs page covers some of the most common mid-treatment questions.

How does the newer Wegovy 7.2 mg dose affect the timeline?

In January 2026 the MHRA approved a higher 7.2 mg maintenance dose of Wegovy, and on 14 April 2026 a dedicated single-dose 7.2 mg pen was approved for adults with a BMI of 30 or above. Trial data at this dose showed an average weight reduction of around 20.7% over 72 weeks, approaching the results seen with tirzepatide at its highest doses. The dose-escalation process still begins at 0.25 mg, so the early timeline is unchanged; the difference is where the ceiling sits.

The higher dose will not automatically be appropriate for everyone, and your prescriber determines whether you are a suitable candidate. If you are already established on Wegovy and considering how your treatment might progress, that conversation belongs in a clinical review rather than on a website. You can explore what is currently available through nume's service on the getting started with Wegovy page, or read about how long before you see results on Wegovy for a broader look at the pharmacology behind these timelines. The about us page explains the clinical oversight behind every prescription issued through the service.

If you are ready to find out whether Wegovy suits you, start your free consultation and a GPhC-registered prescriber will review your details the same day.